

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
23 June 2005 (23.06.2005)

PCT

(10) International Publication Number
WO 2005/056595 A2

(51) International Patent Classification⁷: **C07K 14/705**

(21) International Application Number:
PCT/GB2004/005100

(22) International Filing Date: 6 December 2004 (06.12.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0328363.7 6 December 2003 (06.12.2003) GB

(71) Applicant (for all designated States except US): IMPERIAL COLLEGE INNOVATIONS LIMITED [GB/GB]; Sherfield Building, Imperial College, London SW7 2AZ (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): STAUSS, Hans, Josef [DE/GB]; Department of Immunology, Hammersmith Hospital Campus, Imperial College London, Du Cane Road, London W12 0NN (GB). GAO, Liquan [GB/GB]; Dept. of Immunology, Hammersmith Hospital

Campus, Imperial College London, Du Cane Road, London W12 0NN (GB). XUE, Shao-An [CN/GB]; Dept. of Immunology, Hammersmith Hospital Campus, Imperial College London, Du Cane Road, London W12 0NN (GB).

(74) Agent: MILES, John; Eric Potter Clarkson, Park View House, 58 The Ropewalk, Nottingham NG1 5DD (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HI, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,

[Continued on next page]

(54) Title: THERAPEUTICALLY USEFUL MOLECULES

Human TCR V α -1.5 (V α -8.2) coding sequence

```
ATGCTCCTGC TGCTCGTCCC AGTGCTCGAG GTGATTTTA CTCTGGGAGG
AACCAGAGCC CAGTCGGTGA CCCAGCTTGA CAGCCACGTC TCTGTCTCG
AAGGAACCCC GGTGCTGCTG AGGTGCAACT ACTCATCTTC TTATTCACCA
TCTCTCTCT GGATGTGCA ACACCCAAAC AAGGGACTTCC AGCTTCTCCT
GAAGTACACA TCAGCGGCCA CCCTGGTTAA AGGCATCAAC GGTTTGAGGG
CTGAATTAA GAAGAGTGAAC ACCCTCTTCC ACCTGACGAA ACCCTCAGCC
CATATGAGCG ACGCCGCTGA GTACTCTGT GTTGTGAGTC CTTTTTCAGG
AGGAGGGTGT GACGGGACTCA CCTTTGGCAA AGGGACTCAT CTAATCATCC
AGCCCTATAT CCAGAACCC GACCCCTGCC TGTAACAGCT GAGAGACTCT
AAATCCAGTG ACAAGTCTGT CTGCCATTAC ACCGATTTTG ATTCTCAAAC
AAATGTGTCA CAAAGTAAGG ATTCTGATGT GTATATCACA GACAAAAGCTG
TGCTAGACAT GAGGTCTATG GACTTCAGA GCAACAGTGC TGTGGCCTGG
AGCAACAAAT CTGACTTTCG ATGTGCAAAC GCCTTCAACA ACAGCATTAT
TCCAGAACAG ACCTTCTTCC CCAGCCCCAGA AAGTTCTGT GATGTCAAGC
TGGTCGAGAA AAGCTTTGAA ACAGATACGA ACCTAAACTT TCAAACACTG
TCAGTGTATT GGTTCCGAAT CCTCCCTCTG AAAGTGGCCG GGTTTAATCT
GCTCATGACG CTGCGGGCTGT GGTCAGCTG A
```

WO 2005/056595 A2

(57) Abstract: A T cell receptor molecule (TCR) containing an alpha chain portion and a beta chain portion wherein the alpha chain portion contains three complementarity determining regions (CDRs): CDR1 α : SSYSPS CDR2 α : YTSAATL CDR3 α : VVSPF-SGGGADGLT or comprising or consisting of SPFSGGGADGLT and the beta chain portion contains three complementarity determining regions (CDRs): CDR1 β : DFQATT CDR2 β : SNEGSKA CDR3 β : comprising SARDGEG or comprising or consisting of RDGGEGETQY, or wherein up to three amino acid residues in one or more CDRs are replaced by another amino acid residue. The invention also includes polynucleotides encoding the TCR molecules, and host cells containing the said polynucleotides. Patient derived T cells may have the polynucleotides encoding the TCR molecules introduced therein, and the engineered T cells may be introduced into the patient in order to combat a WT1-expressing malignancy.

WO 2005/056595 A2



SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- *without international search report and to be republished upon receipt of that report*